Amantadine in catatonia due to major depressive disorder in a medically ill patient [11]

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 19, Issue 4, 2007, Pages 480-481

  Goforth, Harold ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LORAZEPAM; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RISPERIDONE; SERTRALINE;

ADULT; CASE REPORT; CATATONIA; CATATONIC SCHIZOPHRENIA; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LETTER; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UREMIA;

EID: 36348939903     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2007.19.4.480     Document Type: Letter

References (5)

1. Rosebush PI, Hildebrand AN, Furlong BG, et al: Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357-362
2. Taylor MA: Catatonia. A review of a behavioral neurological syndrome. Neuropsychiatry, Neuropsychol Behav Neurol 1990; 3:48-72
3. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158:1367-1377
4. Carroll BT, Thomas C, Jayanti K: Amantadine and memantine in catatonic schizophrenia. Annals of Clinical Psychiatry 2006; 18:133-134
5. Thomas C, Carroll BT, Maley JT, et al: Memantine in catatonic schizophrenia. Am J Psychiatry 2005; 162:626